A Study of Maribavir in Japanese People With Cytomegalovirus (CMV) Infection

PHASE3CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

January 18, 2022

Primary Completion Date

June 27, 2023

Study Completion Date

June 27, 2023

Conditions
Cytomegalovirus (CMV)
Interventions
DRUG

Maribavir

Maribavir tablets

Trial Locations (20)

Unknown

Ehime University Hospital, Tōon

Kyushu University Hospital, Fukuoka

Hokkaido University Hospital, Sapporo

Sapporo City General Hospital, Sapporo

Sapporo Hokuyu Hospital, Sapporo

University of Tsukuba Hospital, Tsukuba

Imamura General Hospital, Kagoshima

Osaka International Cancer Institute, Osaka

Osaka University Hospital, Suita

Jichi Medical University Hospital, Shimotsuke

The Jikei University Hospital, Minato-ku

Toranomon Hospital, Minato-ku

Keio University Hospital, Shinjuku-ku

Yochomachi Clinic, Shinjuku-ku

Chiba University Hospital, Chiba

Fukushima Medical University Hospital, Fukushima

Kyoto University Hospital, Kyoto

Okayama University Hospital, Okayama

Osaka Metropolitan University Hospital, Osaka

Jichi Medical University Saitama Medical Center, Saitama

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY

NCT05137717 - A Study of Maribavir in Japanese People With Cytomegalovirus (CMV) Infection | Biotech Hunter | Biotech Hunter